LPCN (Lipocine) Shares Buyback Ratio %: -53.41 (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LPCN Lipocine Inc LPCN
49 GF Score
Price $2.09
GF Value $1.31
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lipocine Shares Buyback Ratio %?

Lipocine LPCN 49 Shares Buyback Ratio % is -53.41 as of Aug. 22, 2026. GuruFocus rates LPCN with a GF Score™ of 49/100 and a GF Value™ of $1.31 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Lipocine's current shares buyback ratio was -53.41%.

Lipocine Shares Buyback Ratio % Related Terms

Lipocine Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Lipocine's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Shares Buyback Ratio % Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.07 -0.25 -2.09 -0.60 -15.15

Lipocine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -0.86 -13.62 -21.39 -10.29
LPCN
49GF Score
Lipocine Inc LPCN
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine Shares Buyback Ratio % Calculation

Lipocine's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(5.348 - 6.158) / 5.348
=-15.15%

Lipocine's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2026 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Mar. 2026 )
=(7.475 - 8.244) / 7.475
=-10.29%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -53.41 mean?
Lipocine (LPCN) has a Shares Buyback Ratio % of -53.41 as of Aug. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Lipocine and its competitors.
Is Lipocine's Shares Buyback Ratio % too high?
Lipocine's current Shares Buyback Ratio % is -53.41. Overall, Lipocine has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Shares Buyback Ratio % compare to NXTC and VYNE?
Lipocine's Shares Buyback Ratio % of -53.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Lipocine and its competitors. Lipocine's current Shares Buyback Ratio % is -53.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Based on GuruFocus' analysis, Lipocine (LPCN) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.31, compared to a current price of $2.09 — trading 59.5% above its estimated fair value. The current Shares Buyback Ratio % is -53.41. Lipocine's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Lipocine (LPCN), the current Shares Buyback Ratio % is -53.41 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (LPCN) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of $2.09 is trading 59.5% above its estimated GF Value™ of $1.31. GuruFocus considers Lipocine to be Significantly Overvalued.

Key valuation signals for LPCN:

  • Shares Buyback Ratio %: -53.41
  • GF Value™: $1.31 vs. price of $2.09 (59.5% above fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the LPCN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lipocine Business Description

Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
49GF Score

Get the complete analysis for LPCN

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.09
Price
$1.31
GF Value